Companies are rushing to capitalize on a hot new gene technology before a high-stakes patent dispute has been settled. The gene-editing tool, known as Crispr-Cas9, serves as a kind of multipurpose molecular scissors that can cut DNA and make repairs and insert changes into genes.
Read Full Article »
